CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Cannabis Bioscience International Holdings (CBIH) announced the completion of a patent-ready melanoma research program focused on cannabinoid science and epigenetic regulation. The initiative adds to the company's portfolio of 25 finalized patent applications, with 10 already submitted to the USPTO and 15 ready for submission.
Key figures
- Total ip assets
- 100
- Uspto submitted
- 10
- Ready for submission
- 15
- Total patent applications
- 25
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.